bicalutamide apotex 50 mg tabletki powlekane
apotex europe b.v. - bicalutamidum - tabletki powlekane - 50 mg
bicalutamide polpharma 50 mg 50 mg tabletki powlekane
zakłady farmaceutyczne polpharma s.a. - bicalutamidum - tabletki powlekane - 50 mg
bicalutamide teva 50 mg tabletki powlekane
teva pharmaceuticals polska sp. z o.o. - bicalutamidum - tabletki powlekane - 50 mg
binabic 150 mg tabletki powlekane
vipharm s.a. - bicalutamidum - tabletki powlekane - 150 mg
binabic 50 mg tabletki powlekane
vipharm s.a. - bicalutamidum - tabletki powlekane - 50 mg
casodex 50 mg tabletki powlekane
astrazeneca ab - bicalutamidum - tabletki powlekane - 50 mg
binabic 50 mg tabletki powlekane
inpharm sp. z o.o. - bicalutamidum - tabletki powlekane - 50 mg
binabic 50 mg tabletki powlekane
delfarma sp. z o.o. - bicalutamidum - tabletki powlekane - 50 mg
casodex 50 mg tabletki powlekane
forfarm sp. z o.o. - tabletki powlekane - 50 mg
xtandi
astellas pharma europe b.v. - enzalutamid - nowotwory stercza - terapia endokrynologiczna - xtandi is indicated for:the treatment of adult men with metastatic hormone-sensitive prostate cancer (mhspc) in combination with androgen deprivation therapy (see section 5. the treatment of adult men with high-risk non-metastatic castration-resistant prostate cancer (crpc) (see section 5. the treatment of adult men with metastatic crpc who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicated (see section 5. the treatment of adult men with metastatic crpc whose disease has progressed on or after docetaxel therapy.